Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Iveric Bio’s AMD Drug Accepted for EMA Review: Astellas
Astellas Pharma said on August 18 that European regulatory authorities have accepted for review a marketing authorization application for avacincaptad pegol for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).Avacincaptad pegol is a complement C5 inhibitor…
To read the full story
Related Article
- Astellas Pulls EU Filing for Geographic Atrophy Drug
October 29, 2024
- Izervay Slows Geographic Atrophy Lesion Growth through 2 Years: Astellas
November 7, 2023
- Iveric Bio’s AMD Med Nets Positive PIII Topline Data in Geographic Atrophy: Astellas
September 20, 2023
- Iveric Bio’s AMD Drug Approved in US, Launch Set for This Month: Astellas
August 8, 2023
BUSINESS
- BMS Files Breyanzi for Relapsed/Refractory CLL, SLL in Japan
June 1, 2026
- Astellas Rebuts ISS Opposition to Outside Director Nominee
June 1, 2026
- Meiji Backs US Fund Supporting Pandemic Preparedness
June 1, 2026
- Kaken, Gilead Ink Japan Sales Partnership for Seladelpar
June 1, 2026
- Shionogi’s OIC Drug Naldemedine Bags Approval in China
June 1, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…